Christel Franchet
Corporate Officer/Principal presso Domain Therapeutics SA
Profilo
Christel Franchet is the founder of Euroclide SA, which was founded in 2001.
She is currently the Head of Biology Department at Domain Therapeutics SA. Dr. Franchet's former position was as a Principal at Hoffmann La Roche France in 2001.
She received a doctorate degree from the University of Strasbourg in 2001.
Posizioni attive di Christel Franchet
Società | Posizione | Inizio |
---|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Corporate Officer/Principal | - |
Precedenti posizioni note di Christel Franchet
Società | Posizione | Fine |
---|---|---|
Hoffmann La Roche France | Corporate Officer/Principal | 01/01/2001 |
Euroclide SA
Euroclide SA Miscellaneous Commercial ServicesCommercial Services Part of Domain Therapeutics SA, Euroclide SA is a French drug research company. The company was founded by Christel Franchet. Euroclide was acquired by Domain Therapeutics SA on December 22, 2003. | Fondatore | - |
Formazione di Christel Franchet
University of Strasbourg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Hoffmann La Roche France | |
Euroclide SA
Euroclide SA Miscellaneous Commercial ServicesCommercial Services Part of Domain Therapeutics SA, Euroclide SA is a French drug research company. The company was founded by Christel Franchet. Euroclide was acquired by Domain Therapeutics SA on December 22, 2003. | Commercial Services |
- Borsa valori
- Insiders
- Christel Franchet